---
search:
  boost: 3
---

# Hereditary Angioedema

This is a subcategory of Respiratory Agents.

## Decision Trees

- [Respiratory - Hereditary Angioedema- Non-Preferred - Berinert, Cinryze, Icatibant Acetate, Kalbitor](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUN1pRNjNUSFpETE41UURPTEwwUlJVTlNDUiQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [Respiratory - Hereditary Angioedema- Preferred - Haegarda, Ruconest, Takhzyro](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURE1EMkxPQzFLUDcxREpQRFU4SU03TzJIVSQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred              | Generic Name | Quantity | Time (Days) |
|:-----------------------|:-------------|:--------:|:-----------:|
| Haegarda <sup>PA</sup> |              |          |             |
| Ruconest <sup>PA</sup> |              |          |             |
| Takhzyro <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred     | Generic Name | Quantity | Time (Days) |
|:------------------|:-------------|:--------:|:-----------:|
| Berinert          |              |          |             |
| Cinryze           |              |          |             |
| Icatibant Acetate |              |          |             |
| Kalbitor          |              |          |             |

## Authorizations

**Length of Authorizations**: Initial: 90 days; Subsequent: 180 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Must provide documentation of diagnosis (i.e., C1-INH deficiency or dysfunction (Type I or
II HAE)) and whether the drug will be used for prophylaxis or treatment
- Must provide documentation of at-home administration


### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **60 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=96){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=31){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
